P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting

Our findings provide a rationale to explore the combination of CD1d-Vδ2 bsTCE and the IMiD lenalidomide in patients with CD1d-expressing hematological malignancies.

P1/2, N=300, Active, not recruiting, Australasian Leukaemia & Lymphoma Group | Recruiting --> Active, not recruiting

In multivariate analysis, receiving an alkylator based induction, radiation therapy, achieving a complete response after auto-SCT, use of cyclophosphamide for stem cell mobilization and lenalidomide maintenance were independent predictors of developing SHM. Patients with MM who developed a SHM had an inferior overall survival (OS). Given the median OS for MM continues to improve, monitoring for SHM and risk mitigation strategies is crucial.

However, various factors can lead to failure in hematopoietic stem cell mobilization in some patients, including age, type of malignancy, chemotherapy regimens (such as fludarabine, Melphalan, and Lenalidomide), radiotherapy, bone marrow cellularity, and comorbidities. It is crucial to recognize that diabetes can significantly affect the outcomes of hematopoietic stem cell transplantation. Factors such as poor stem cell mobilization, prolonged engraftment times, and increased need for blood product transfusions underscore the importance of considering diabetes in HSCT candidates.

Treatment with low-dose Len in transfusion-independent del(5q) MDS reduced the mutational burden of most genes and did not promote the expansion of preexisting clones or AML progression, especially TP53-mutated clones. Early administration of Len in del(5q) MDS patients without TD may be an effective therapeutic approach with a manageable safety profile regarding clonal evolution.

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed

Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted.

In contrast, elevations in general inflammatory markers (white blood cell count, eosinophils, and C-reactive protein) or in lactate dehydrogenase, an indicator of atopic dermatitis, were observed in only a minority of events. These findings suggest that TARC may be a useful biomarker for identifying lenalidomide-induced rash and may aid in optimizing clinical management while maintaining treatment continuity.

This bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.

P=N/A, N=911, Completed, Celgene | Active, not recruiting --> Completed

P=N/A, N=100, Completed, Fondazione IRCCS Policlinico San Matteo di Pavia